Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.36 CAD | +3.96% | +0.85% | +461.90% |
May. 22 | Medicenna to Present Clinical Update on MDNA11 ABILITY-1 Trial at Sachs Oncology Innovation Forum | MT |
May. 13 | Medicenna Says ABILITY-1 Abstract Withdrawn by ASCO Program Committee | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+461.90% | 124M | |
+48.12% | 56.69B | |
-2.88% | 41B | |
+38.14% | 38.11B | |
-11.22% | 26.89B | |
+15.38% | 25.59B | |
-22.98% | 18.59B | |
+0.05% | 12.39B | |
+26.69% | 11.99B | |
+22.77% | 11.88B |
- Stock Market
- Equities
- MDNA Stock
- News Medicenna Therapeutics Corp.
- HC Wainwright Adjusts Medicenna Therapeutics' Price Target to $4 From $5, Keeps Buy Rating